Sorafenib improves rituximab and ofatumumab efficacy by decreasing the expression of complement regulatory proteins

por Dwojak, M, Bobrowicz, M, Bil, J, Bojarczuk, K, Pyrzynska, B, Siernicka, M, Malenda, A, Lech-Maranda, E, Tomczak, W, Giannopoulos, K, Golab, J, Winiarska, M
Publicado 2015

P1221: DIFFUSE LARGE B-CELL LYMPHOMA RICHTER SYNDROME IN CHRONIC LYMPHOCYTIC LEUKEMIA – A RETROSPECTIVE ANALYSIS OF TREATMENT OUTCOMES IN POLISH ADULT LEUKEMIA STUDY GROUP

por Sośnia, O., Danecki, M., Wąsik-Szczepanek, E., Tryc-Szponder, J., Iskierka-Jażdżewska, E., Majeranowski, A., Pruszczyk, K., Krzemień, H., Bołkun, L., Paszkiewicz-Kozik, E., Drozd-Sokołowska, J., Kwiatkowski, J., Wiśniewska-Organek, D., Budziszewska, B., Jamroziak, K., Hus, I., Lech-Marańda, E., Puła, B.
Publicado 2022

P1101: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY

por Eyre, T. A., Wang, M. L., Shah, N. N., Alencar, A. J., Gerson, J. N., Patel, M. R., Fakhri, B., Vandenberghe, E., Jurczak, W., Tan, X. N., Lewis, K. L., Fenske, T., Wang, Y., Coombs, C. C., Flinn, I., Lewis, D., Le Gouill, S., Gandhi, M., Chay, C., Palomba, M. L., Woyach, J. A., Pagel, J. M., Lamanna, N., Sharman, J. P., Andorsky, D. J., Cohen, J. B., Barve, M. A., Ghia, P., Yin, M., Zinzani, P. L., Ujjani, C., Koh, Y., Izutsu, K., Lech-Maranda, E., Kherani, J., Tam, C., Sundaram, S., Nair, B., Tsai, D. E., Balbas, M., Mato, A. R., Cheah, C. Y.
Publicado 2022